FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1071-1080 March 17, 2005 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Drazen, J. M. Editorial by Psaty, B. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern.

Methods We reviewed all potentially serious cardiovascular events among 2035 patients with a history of colorectal neoplasia who were enrolled in a trial comparing two doses of celecoxib (200 mg or 400 mg twice daily) with placebo for the prevention of colorectal adenomas. All deaths were categorized as cardiovascular or noncardiovascular, and nonfatal cardiovascular events were categorized in a blinded fashion according to a prespecified scheme.

Results For all patients except those who died, 2.8 to 3.1 years of follow-up data were available. A composite cardiovascular end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure was reached in 7 of 679 patients in the placebo group (1.0 percent), as compared with 16 of 685 patients receiving 200 mg of celecoxib twice daily (2.3 percent; hazard ratio, 2.3; 95 percent confidence interval, 0.9 to 5.5) and with 23 of 671 patients receiving 400 mg of celecoxib twice daily (3.4 percent; hazard ratio, 3.4; 95 percent confidence interval, 1.4 to 7.8). Similar trends were observed for other composite end points. On the basis of these observations, the data and safety monitoring board recommended early discontinuation of the study drug.

Conclusions Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure. In light of recent reports of cardiovascular harm associated with treatment with other agents in this class, these data provide further evidence that the use of COX-2 inhibitors may increase the risk of serious cardiovascular events.

Source Information

From the Cardiovascular Division, Departments of Medicine (S.D.S., M.A.P., P.F.) and Surgery (M.B.), Brigham and Women's Hospital, Harvard Medical School, Boston; Western Infirmary, University of Glasgow, Glasgow, Scotland (J.J.V.M.); Statistics Collaborative, Washington, D.C. (J.W., R.F.); National Cancer Institute, Bethesda, Md. (W.F.A., E.H.); and Memorial Sloan-Kettering Cancer Center, New York (A.Z.).

This article was published at www.nejm.org on February 15, 2005.

Address reprint requests to Dr. Solomon at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at ssolomon{at}rics.bwh.harvard.edu.

Full Text of this Article

Related Letters:

Cardiovascular Risk Associated with Celecoxib
Brophy J. M., Solomon S. D., Wittes J., McMurray J., the APC Study Cardiovascular Safety Committee and Investigators , Psaty B. M., Furberg C. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2648-2650, Jun 23, 2005. Correspondence

This article has been cited by other articles:

• Steele, V. E., Rao, C. V., Zhang, Y., Patlolla, J., Boring, D., Kopelovich, L., Juliana, M. M., Grubbs, C. J., Lubet, R. A. (2009). Chemopreventive Efficacy of Naproxen and Nitric Oxide-naproxen in Rodent Models of Colon, Urinary Bladder, and Mammary Cancers. Cancer Prevention Research 2: 951-956 [Abstract] [Full Text]  
• Antonarakis, E. S., Heath, E. I., Walczak, J. R., Nelson, W. G., Fedor, H., De Marzo, A. M., Zahurak, M. L., Piantadosi, S., Dannenberg, A. J., Gurganus, R. T., Baker, S. D., Parnes, H. L., DeWeese, T. L., Partin, A. W., Carducci, M. A. (2009). Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. JCO 27: 4986-4993 [Abstract] [Full Text]  
• Wittes, J. (2009). Comment on paper by Crowe et al. Clin Trials 6: 441-442  
• Chilet-Rosell, E., Ruiz-Cantero, M. T., Horga, J. F. (2009). Women's health and gender-based clinical trials on etoricoxib: methodological gender bias. J Public Health (Oxf) 31: 434-445 [Abstract] [Full Text]  
• Neugut, A. I. (2009). Aspirin as Adjuvant Therapy for Colorectal Cancer: A Promising New Twist for an Old Drug. JAMA 302: 688-689 [Full Text]  
• Thiel, A., Ganesan, A., Mrena, J., Junnila, S., Nykanen, A., Hemmes, A., Tai, H.-H., Monni, O., Kokkola, A., Haglund, C., Petrova, T. V., Ristimaki, A. (2009). 15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer. Clin. Cancer Res. 15: 4572-4580 [Abstract] [Full Text]  
• Lippman, S. M., Hawk, E. T. (2009). Cancer Prevention: From 1727 to Milestones of the Past 100 Years. Cancer Res. 69: 5269-5284 [Abstract] [Full Text]  
• Krum, H., Curtis, S. P., Kaur, A., Wang, H., Smugar, S. S., Weir, M. R., Laine, L., Brater, D. C., Cannon, C. P. (2009). Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail 11: 542-550 [Abstract] [Full Text]  
• Lippman, S. M. (2009). Cancer Prevention Research: Back to the Future. Cancer Prevention Research 2: 503-513 [Full Text]  
• Wang, D., Patel, V. V., Ricciotti, E., Zhou, R., Levin, M. D., Gao, E., Yu, Z., Ferrari, V. A., Lu, M. M., Xu, J., Zhang, H., Hui, Y., Cheng, Y., Petrenko, N., Yu, Y., FitzGerald, G. A. (2009). Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc. Natl. Acad. Sci. USA 106: 7548-7552 [Abstract] [Full Text]  
• Solomon, D. H. (2009). Searching for a Safe Analgesic in Patients With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes 2: 146-147 [Full Text]  
• van der Linden, M W, van der Bij, S, Welsing, P, Kuipers, E J, Herings, R M C (2009). The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 68: 668-673 [Abstract] [Full Text]  
• Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Breazna, A., Kim, K., Tang, J., Rosenstein, R. B., Umar, A., Bagheri, D., Collins, N. T., Burn, J., Chung, D. C., Dewar, T., Foley, T. R., Hoffman, N., Macrae, F., Pruitt, R. E., Saltzman, J. R., Salzberg, B., Sylwestrowicz, T., Hawk, E. T., for the Adenoma Prevention with Celecoxib Study In, (2009). Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research 2: 310-321 [Abstract] [Full Text]  
• Duffield-Lillico, A. J., Boyle, J. O., Zhou, X. K., Ghosh, A., Butala, G. S., Subbaramaiah, K., Newman, R. A., Morrow, J. D., Milne, G. L., Dannenberg, A. J. (2009). Levels of Prostaglandin E Metabolite and Leukotriene E4 Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway. Cancer Prevention Research 2: 322-329 [Abstract] [Full Text]  
• DuBois, R. N. (2009). New, Long-term Insights from the Adenoma Prevention with Celecoxib Trial on a Promising but Troubled Class of Drugs. Cancer Prevention Research 2: 285-287 [Full Text]  
• Combe, B., Swergold, G., McLay, J., McCarthy, T., Zerbini, C., Emery, P., Connors, L., Kaur, A., Curtis, S., Laine, L., Cannon, C. P. (2009). Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 48: 425-432 [Abstract] [Full Text]  
• Heiduschka, G., Erovic, B. M., Vormittag, L., Skoda, C., Martinek, H., Brunner, M., Ehrenberger, K., Thurnher, D. (2009). 7{beta}-Hydroxycholesterol Induces Apoptosis and Regulates Cyclooxygenase 2 in Head and Neck Squamous Cell Carcinoma. Arch Otolaryngol Head Neck Surg 135: 261-267 [Abstract] [Full Text]  
• Song, S., Guan, B., Men, T., Hoque, A., Lotan, R., Xu, X.-C. (2009). Antitumor Effect of Retinoic Acid Receptor-{beta}2 Associated with Suppression of Cyclooxygenase-2. Cancer Prevention Research 2: 274-280 [Abstract] [Full Text]  
• Zell, J. A., Pelot, D., Chen, W.-P., McLaren, C. E., Gerner, E. W., Meyskens, F. L. (2009). Risk of Cardiovascular Events in a Randomized Placebo-Controlled, Double-Blind Trial of Difluoromethylornithine plus Sulindac for the Prevention of Sporadic Colorectal Adenomas. Cancer Prevention Research 2: 209-212 [Abstract] [Full Text]  
• Suissa, S. (2009). Statistical methods in pharmacoepidemiology: advances and challenges. Stat Methods Med Res 18: 3-6  
• Patrono, C., Baigent, C. (2009). Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges. Mol. Interv. 9: 31-39 [Abstract] [Full Text]  
• Suh, Y., Afaq, F., Johnson, J. J., Mukhtar, H. (2009). A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-{kappa}B-signaling pathways. Carcinogenesis 30: 300-307 [Abstract] [Full Text]  
• Kellogg, A. P., Converso, K., Wiggin, T., Stevens, M., Pop-Busui, R. (2009). Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am. J. Physiol. Heart Circ. Physiol. 296: H453-H461 [Abstract] [Full Text]  
• Gislason, G. H., Rasmussen, J. N., Abildstrom, S. Z., Schramm, T. K., Hansen, M. L., Fosbol, E. L., Sorensen, R., Folke, F., Buch, P., Gadsboll, N., Rasmussen, S., Poulsen, H. E., Kober, L., Madsen, M., Torp-Pedersen, C. (2009). Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure. Arch Intern Med 169: 141-149 [Abstract] [Full Text]  
• FATIMA, N., CHELIUS, D., LUKE, B. T., YI, M., ZHANG, T., STAUFFER, S., STEPHENS, R., LYNCH, P., MILLER, K., GUSZCZYNSKI, T., BORING, D., GREENWALD, P., ALI, I. U. (2009). Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. Cancer Genomics Proteomics 6: 41-49 [Abstract] [Full Text]  
• Schug, S. A., Joshi, G. P., Camu, F., Pan, S., Cheung, R. (2009). Cardiovascular Safety of the Cyclooxygenase-2 Selective Inhibitors Parecoxib and Valdecoxib in the Postoperative Setting: An Analysis of Integrated Data. Anesth. Analg. 108: 299-307 [Abstract] [Full Text]  
• Warner, J. J., Weideman, R. A., Kelly, K. C., Brilakis, E. S., Banerjee, S., Cunningham, F., Harford, W. V., Kazi, S., Little, B. B., Cryer, B. (2008). The Risk of Acute Myocardial Infarction with Etodolac Is not Increased Compared to Naproxen: A Historical Cohort Analysis of a Generic COX-2 Selective Inhibitor. J CARDIOVASC PHARMACOL THER 13: 252-260 [Abstract]  
• Goodman, G. E. (2008). Assessing Toxicity in Cancer Chemoprevention Trials: The Other Side of the Coin. Cancer Prevention Research 1: 499-502 [Full Text]  
• Lam, E. T., O'Bryant, C. L., Basche, M., Gustafson, D. L., Serkova, N., Baron, A., Holden, S. N., Dancey, J., Eckhardt, S. G., Gore, L. (2008). A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular Cancer Therapeutics 7: 3685-3694 [Abstract] [Full Text]  
• Mahoney, M. C., Bevers, T., Linos, E., Willett, W. C. (2008). Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction. CA Cancer J Clin 0: CA.2008.0016v1-CA.2008.0016 [Abstract] [Full Text]  
• Go, A. S., Magid, D. J., Wells, B., Sung, S. H., Cassidy-Bushrow, A. E., Greenlee, R. T., Langer, R. D., Lieu, T. A., Margolis, K. L., Masoudi, F. A., McNeal, C. J., Murata, G. H., Newton, K. M., Novotny, R., Reynolds, K., Roblin, D. W., Smith, D. H., Vupputuri, S., White, R. E., Olson, J., Rumsfeld, J. S., Gurwitz, J. H. (2008). The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research. Circ Cardiovasc Qual Outcomes 1: 138-147 [Abstract] [Full Text]  
• Scott, P. A, Kingsley, G. H., Scott, D. L (2008). Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 10: 1102-1107 [Abstract] [Full Text]  
• Szabo, E. (2008). Assessing Efficacy in Early-Phase Cancer Prevention Trials: The Case of Oral Premalignancy. Cancer Prevention Research 1: 312-315 [Full Text]  
• Nemenoff, R., Meyer, A. M., Hudish, T. M., Mozer, A. B., Snee, A., Narumiya, S., Stearman, R. S., Winn, R. A., Weiser-Evans, M., Geraci, M. W., Keith, R. L. (2008). Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator-Activated Receptor {gamma}. Cancer Prevention Research 1: 349-356 [Abstract] [Full Text]  
• Hong, D., Flood, P., Diaz, G. (2008). The Side Effects of Morphine and Hydromorphone Patient-Controlled Analgesia. Anesth. Analg. 107: 1384-1389 [Abstract] [Full Text]  
• Li, H., Hortmann, M., Daiber, A., Oelze, M., Ostad, M. A., Schwarz, P. M., Xu, H., Xia, N., Kleschyov, A. L., Mang, C., Warnholtz, A., Munzel, T., Forstermann, U. (2008). Cyclooxygenase 2-Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs Induce Oxidative Stress by Up-Regulating Vascular NADPH Oxidases. J. Pharmacol. Exp. Ther. 326: 745-753 [Abstract] [Full Text]  
• Reed, S. D., Anstrom, K. J., Seils, D. M., Califf, R. M., Schulman, K. A. (2008). Use Of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs. Health Aff (Millwood) 27: w360-w370 [Abstract] [Full Text]  
• Arber, N. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point. Cancer Epidemiol. Biomarkers Prev. 17: 1852-1857 [Abstract] [Full Text]  
• Jankowski, J., Hunt, R. (2008). Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint. Cancer Epidemiol. Biomarkers Prev. 17: 1858-1861 [Abstract] [Full Text]  
• Januzzi, J. L. Jr (2008). Use of Biomarkers to Predict Cardiac Risk from Medications: Getting to the Heart of the Matter. Clin. Chem. 54: 1107-1109 [Full Text]  
• Markowitz, S. D. (2008). Colorectal Neoplasia Goes with the Flow: Prostaglandin Transport and Termination. Cancer Prevention Research 1: 77-79 [Full Text]  
• Brune, K., Katus, H. A., Moecks, J., Spanuth, E., Jaffe, A. S., Giannitsis, E. (2008). N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial. Clin. Chem. 54: 1149-1157 [Abstract] [Full Text]  
• Roumie, C. L., Mitchel, E. F. Jr, Kaltenbach, L., Arbogast, P. G., Gideon, P., Griffin, M. R. (2008). Nonaspirin NSAIDs, Cyclooxygenase 2 Inhibitors, and the Risk for Stroke. Stroke 39: 2037-2045 [Abstract] [Full Text]  
• Kvien, T K, Fjeld, E, Slatkowsky-Christensen, B, Nichols, M, Zhang, Y, Proven, A, Mikkelsen, K, Palm, O, Borisy, A A, Lessem, J (2008). Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann Rheum Dis 67: 942-948 [Abstract] [Full Text]  
• Haag, M. D. M., Bos, M. J., Hofman, A., Koudstaal, P. J., Breteler, M. M. B., Stricker, B. H. C. (2008). Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke. Arch Intern Med 168: 1219-1224 [Abstract] [Full Text]  
• Sporn, M. B., Hong, W. K. (2008). Clinical Prevention of Recurrence of Colorectal Adenomas by the Combination of Difluoromethylornithine and Sulindac: An Important Milestone. Cancer Prevention Research 1: 9-11 [Full Text]  
• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Nakanishi, M., Montrose, D. C., Clark, P., Nambiar, P. R., Belinsky, G. S., Claffey, K. P., Xu, D., Rosenberg, D. W. (2008). Genetic Deletion of mPGES-1 Suppresses Intestinal Tumorigenesis. Cancer Res. 68: 3251-3259 [Abstract] [Full Text]  
• Blaine, T., Moskowitz, R., Udell, J., Skyhar, M., Levin, R., Friedlander, J., Daley, M., Altman, R. (2008). Treatment of Persistent Shoulder Pain with Sodium Hyaluronate: A Randomized, Controlled Trial. A Multicenter Study. JBJS 90: 970-979 [Abstract] [Full Text]  
• Kohne, C.-H., De Greve, J., Hartmann, J. T., Lang, I., Vergauwe, P., Becker, K., Braumann, D., Joosens, E., Muller, L., Janssens, J., Bokemeyer, C., Reimer, P., Link, H., Spath-Schwalbe, E., Wilke, H.-J., Bleiberg, H., Van Den Brande, J., Debois, M., Bethe, U., Van Cutsem, E. (2008). Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 19: 920-926 [Abstract] [Full Text]  
• Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Powell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., Hwa, J. (2008). Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition. Circ. Res. 102: 986-993 [Abstract] [Full Text]  
• Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., Pater, J. L., Goss, P. E., Lance, P., Obara, S., Chew, E. Y., Kim, J., Arndt, G., Hawk, E., for the Cross Trial Safety Assessment Group, (2008). Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation 117: 2104-2113 [Abstract] [Full Text]  
• Hubner, R. A., Muir, K. R., Liu, J.-F., Logan, R. F.A., Grainge, M. J., Houlston, R. S., Members of the UKCAP Consortium, (2008). Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention. Clin. Cancer Res. 14: 2303-2309 [Abstract] [Full Text]  
• Ferrario, C. M. (2008). Editorial: On the selective inhibitors of Cyclooxygenase-2: Do we have a last word?. Ther Adv Cardiovasc Dis 2: 75-78  
• Meinert, C. L (2008). Long-term drug prevention trials. Clin Trials 5: 168-176 [Abstract]  
• Jacobshagen, C., Gruber, M., Teucher, N., Schmidt, A. G., Unsold, B. W., Toischer, K., Nguyen Van, P., Maier, L. S., Kogler, H., Hasenfuss, G. (2008). Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction. Eur J Heart Fail 10: 334-342 [Abstract] [Full Text]  
• van Staa, T P, Smeeth, L, Persson, I, Parkinson, J, Leufkens, H G M (2008). What is the harm-benefit ratio of Cox-2 inhibitors?. Int J Epidemiol 37: 405-413 [Abstract] [Full Text]  
• Dirix, L. Y., Ignacio, J., Nag, S., Bapsy, P., Gomez, H., Raghunadharao, D., Paridaens, R., Jones, S., Falcon, S., Carpentieri, M., Abbattista, A., Lobelle, J.-P. (2008). Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. JCO 26: 1253-1259 [Abstract] [Full Text]  
• Hennekens, C. H., Borzak, S. (2008). Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease. J CARDIOVASC PHARMACOL THER 13: 41-50 [Abstract]  
• Krueger, K, Lino, L, Dore, R, Radominski, S, Zhang, Y, Kaur, A, Simpson, R, Curtis, S (2008). Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 67: 315-322 [Abstract] [Full Text]  
• Subbaramaiah, K., Hudis, C., Chang, S.-H., Hla, T., Dannenberg, A. J. (2008). EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE. J. Biol. Chem. 283: 3433-3444 [Abstract] [Full Text]  
• Frolov, R. V., Berim, I. G., Singh, S. (2008). Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT. J. Biol. Chem. 283: 1518-1524 [Abstract] [Full Text]  
• Harrington, R. A., Hasselblad, V., Califf, R. M. (2008). Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?. J Am Coll Cardiol 51: 33-36 [Full Text]  
• Feng, Y., Neale, J. R., Doll, M. A., Hein, D. W. (2008). Chemoprevention of Arylamine-Induced Colorectal Aberrant Crypts. Exp. Biol. Med. 233: 71-75 [Abstract] [Full Text]  
• Hong, T.-T., Huang, J., Barrett, T. D., Lucchesi, B. R. (2008). Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am. J. Physiol. Heart Circ. Physiol. 294: H145-H155 [Abstract] [Full Text]  
• Zatelli, M. C., Luchin, A., Tagliati, F., Leoni, S., Piccin, D., Bondanelli, M., Rossi, R., degli Uberti, E. C (2007). Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14: 1029-1038 [Abstract] [Full Text]  
• Joshi, G. P., Gertler, R., Fricker, R. (2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg. 105: 1793-1804 [Abstract] [Full Text]  
• Kellogg, A. P., Wiggin, T. D., Larkin, D. D., Hayes, J. M., Stevens, M. J., Pop-Busui, R. (2007). Protective Effects of Cyclooxygenase-2 Gene Inactivation Against Peripheral Nerve Dysfunction and Intraepidermal Nerve Fiber Loss in Experimental Diabetes. Diabetes 56: 2997-3005 [Abstract] [Full Text]  
• Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J (2007). EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66: 1560-1567 [Abstract] [Full Text]  
• Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., Barrueco, J. (2007). Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study. JCO 25: 4779-4786 [Abstract] [Full Text]  
• Logan, R. (2007). Commentary: Preventing colorectal cancer with aspirin what next?. Int J Epidemiol 0: dym204v1-dym204 [Full Text]  
• Buchanan, F. G., Holla, V., Katkuri, S., Matta, P., DuBois, R. N. (2007). Targeting Cyclooxygenase-2 and the Epidermal Growth Factor Receptor for the Prevention and Treatment of Intestinal Cancer. Cancer Res. 67: 9380-9388 [Abstract] [Full Text]  
• Narayanan, B. A., Reddy, B. S., Bosland, M. C., Nargi, D., Horton, L., Randolph, C., Narayanan, N. K. (2007). Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence. Clin. Cancer Res. 13: 5965-5973 [Abstract] [Full Text]  
• Misikangas, M., Pajari, A.-M., Paivarinta, E., Oikarinen, S. I., Rajakangas, J., Marttinen, M., Tanayama, H., Torronen, R., Mutanen, M. (2007). Three Nordic Berries Inhibit Intestinal Tumorigenesis in Multiple Intestinal Neoplasia/+ Mice by Modulating {beta}-Catenin Signaling in the Tumor and Transcription in the Mucosa. J. Nutr. 137: 2285-2290 [Abstract] [Full Text]  
• Scott, P A, Kingsley, G H, Smith, C M, Choy, E H, Scott, D L (2007). Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 66: 1296-1304 [Abstract] [Full Text]  
• Ghosh, M., Wang, H., Ai, Y., Romeo, E., Luyendyk, J. P., Peters, J. M., Mackman, N., Dey, S. K., Hla, T. (2007). COX-2 suppresses tissue factor expression via endocannabinoid-directed PPAR{delta} activation. JEM 204: 2053-2061 [Abstract] [Full Text]  
• Gray, J., Mao, J. T., Szabo, E., Kelley, M., Kurie, J., Bepler, G. (2007). Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). Chest 132: 56S-68S [Abstract] [Full Text]  
• Timmers, L., Pasterkamp, G., de Kleijn, D. P.V. (2007). Microsomal Prostaglandin E2 Synthase: A Safer Target than Cyclooxygenases?. Mol. Interv. 7: 195-199 [Abstract] [Full Text]  
• Nakao, K., Murase, A., Ohshiro, H., Okumura, T., Taniguchi, K., Murata, Y., Masuda, M., Kato, T., Okumura, Y., Takada, J. (2007). CJ-023,423, a Novel, Potent and Selective Prostaglandin EP4 Receptor Antagonist with Antihyperalgesic Properties. J. Pharmacol. Exp. Ther. 322: 686-694 [Abstract] [Full Text]  
• Borer, J. S., Pouleur, H., Abadie, E., Follath, F., Wittes, J., Pfeffer, M. A., Pitt, B., Zannad, F. (2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 28: 1904-1909 [Abstract] [Full Text]  
• Kerr, D. J., Dunn, J. A., Langman, M. J., Smith, J. L., Midgley, R. S.J., Stanley, A., Stokes, J. C., Julier, P., Iveson, C., Duvvuri, R., McConkey, C. C., the VICTOR Trial Group, (2007). Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer. NEJM 357: 360-369 [Abstract] [Full Text]  
• Klein, T., Eltze, M., Grebe, T., Hatzelmann, A., Komhoff, M. (2007). Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 75: 390-397 [Abstract] [Full Text]  
• Hunt, R. H., Choquette, D., Craig, B. N., De Angelis, C., Habal, F., Fulthorpe, G., Stewart, J. I., Turpie, A. G.G., Davis, P. (2007). Approach to managing musculoskeletal pain: Acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?. cfp 53: 1177-1184 [Abstract] [Full Text]  
• Reginster, J Y, Malmstrom, K, Mehta, A, Bergman, G, Ko, A T, Curtis, S P, Reicin, A S (2007). Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis 66: 945-951 [Abstract] [Full Text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B. III, Rothenberg, M., Petrelli, N., Lenz, H.-J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L., O'Connell, M. J. (2007). Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. JCO 25: 2313-2321 [Abstract] [Full Text]  
• Farkouh, M E, Greenberg, J D, Jeger, R V, Ramanathan, K, Verheugt, F W A, Chesebro, J H, Kirshner, H, Hochman, J S, Lay, C L, Ruland, S, Mellein, B, Matchaba, P T, Fuster, V, Abramson, S B (2007). Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 66: 764-770 [Abstract] [Full Text]